Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

5.71EUR
1 Apr 2015
Change (% chg)

€-0.37 (-6.09%)
Prev Close
€6.08
Open
€5.77
Day's High
€6.15
Day's Low
€5.50
Volume
247,630
Avg. Vol
194,500
52-wk High
€10.60
52-wk Low
€3.79

STEN.PA

Chart for STEN.PA

About

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's... (more)

Overall

Beta: 0.91
Market Cap(Mil.): €71.27
Shares Outstanding(Mil.): 11.72
Dividend: --
Yield (%): --

Financials

  STEN.PA Industry Sector
P/E (TTM): -- 41.59 41.18
EPS (TTM): -1.73 -- --
ROI: -56.84 10.90 16.23
ROE: -60.83 12.70 17.07
Search Stocks

BRIEF-Stentys widens FY 2014 net loss to 17.8 million euros

* FY 2014 net loss 17.8 million euros ($19.1 million) versus net loss of 11.7 million euros previous year

31 Mar 2015

BRIEF-Results of Stentys stent trial in myocardial infarction published in EuroIntervention

* One year clinical outcomes of Apposition III registry have been published in EuroIntervention

23 Feb 2015

BRIEF-Stentys announces publication of new self-apposing stent study

* Announces publication of new self-apposing stent study in left main coronary artery

12 Feb 2015

BRIEF-Stentys clinical trial found treatment prevented amputation in 99 pct of cases

* Clinical trial found Stentys treatment prevented amputation in 99 percent of cases

28 Jan 2015

BRIEF-Stentys FY consolidated revenue rises to 3.9 million euros

* FY consolidated revenue 3.9 million euros ($4.4 million) versus 3.4 million euros last year

22 Jan 2015

BRIEF-Stentys signs exclusive agreement with Micell for distribution of its active stent

* Signs exclusive agreement with Micell Technologies Inc for distribution of its active stent

03 Nov 2014

BRIEF-Stentys receives CE marking for its sirolimus-eluting stent

* Receives CE marking for its sirolimus-eluting stent Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)

27 Oct 2014

BRIEF-Stentys wins tender which could be for more than 1,000 stents

* Wins SGH tender which could be for more than 1,000 stents

20 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks